290 related articles for article (PubMed ID: 32482321)
1. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
[TBL] [Abstract][Full Text] [Related]
4. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Lau PK; Ascierto PA; McArthur G
Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
6. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
Rulli E; Legramandi L; Salvati L; Mandala M
Cancer; 2019 Nov; 125(21):3776-3789. PubMed ID: 31287564
[TBL] [Abstract][Full Text] [Related]
7. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Girotti MR; Saturno G; Lorigan P; Marais R
Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
[TBL] [Abstract][Full Text] [Related]
8. [Targeted therapies for melanoma].
Leiter U; Meier F; Garbe C
Hautarzt; 2014 Jul; 65(7):600-6. PubMed ID: 24962553
[TBL] [Abstract][Full Text] [Related]
9. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
10. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
11. Role of Surgery in Combination with Immunotherapy.
Klemen ND; Shindorf ML; Sherry RM
Surg Oncol Clin N Am; 2019 Jul; 28(3):481-487. PubMed ID: 31079801
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
Christiansen SA; Khan S; Gibney GT
Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
14. Metastatic melanoma - a review of current and future treatment options.
Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
16. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
Front Immunol; 2019; 10():990. PubMed ID: 31134073
[TBL] [Abstract][Full Text] [Related]
17. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
18. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.
Rafei-Shamsabadi D; Lehr S; von Bubnoff D; Meiss F
Cancer Immunol Immunother; 2019 Sep; 68(9):1417-1428. PubMed ID: 31422446
[TBL] [Abstract][Full Text] [Related]
19. Indications and options for systemic therapy in melanoma.
Sondak VK; Gibney GT
Surg Clin North Am; 2014 Oct; 94(5):1049-58, viii. PubMed ID: 25245967
[TBL] [Abstract][Full Text] [Related]
20. [Melanoma update].
Longvert C; Saiag P
Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
